Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Market Today: Oil shock, TEAM cuts, LCID robotaxi plans
05:37pm, Thursday, 12'th Mar 2026
Stock News IEA warns of historic oil disruption: Chevron (CVX) and Exxon Mobil (XOM) advanced as the International Energy Agency said Iran's effective closure o
First Look: Oil Surge, Tech Cuts, Cyberattack Hits Stryker
07:38am, Thursday, 12'th Mar 2026
Stock News Oil tops $100 as Hormuz attacks jolt markets: Chevron (CVX) and peers rallied after Brent briefly exceeded $100 a barrel amid Iranian attacks that ch
Market Today: Oracle beats, Zoox-Uber pact, IEA oil move
05:35pm, Wednesday, 11'th Mar 2026
Stock News Inflation steady before oil shock: February CPI rose 2.4% year over year and core 2.5%, in line with forecasts, but markets are looking past the repo
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
02:45pm, Friday, 06'th Mar 2026
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
08:24am, Friday, 06'th Mar 2026
Basel, March 6, 2026 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1 554 shar
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
11:50am, Tuesday, 03'rd Mar 2026
NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU approval.
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
09:30am, Tuesday, 03'rd Mar 2026
Amarin's results depend on a single medicine that is already facing generic competition. By contrast, Novartis has a deep lineup, plenty of growth products, and a solid dividend program.
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement
02:41pm, Saturday, 28'th Feb 2026
Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second lawsuit over the nonconsensual use of HeLa cells.
Banco Santander S.A. Lowers Position in Novartis AG $NVS
05:00am, Saturday, 28'th Feb 2026
Banco Santander S.A. lowered its stake in shares of Novartis AG (NYSE: NVS) by 51.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange C
Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline Potentially unlocks multi-bill
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
06:29am, Friday, 27'th Feb 2026
Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending
Novartis, Genentech file suit alleging illegal importation of prescription drug
03:44pm, Thursday, 26'th Feb 2026
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine. The importation of the drug, which has strict shipping and
Novartis to build radioligand therapy site in Texas to expand US manufacturing
07:41am, Wednesday, 25'th Feb 2026
Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, expanding its U.S. footprint with what will be its first such facility in the state and fifth nationwi
12,349 Shares in Novartis AG $NVS Acquired by Fox Run Management L.L.C.
05:08am, Wednesday, 25'th Feb 2026
Fox Run Management L.L.C. purchased a new position in Novartis AG (NYSE: NVS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm pu
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
04:32pm, Tuesday, 24'th Feb 2026
Novartis' business is resilient, as evidenced by its ability to grow sales despite a major patent cliff. The Swiss healthcare giant's income program is another great attraction for long-term investors
